Infinity Announces the Date of Its Third Quarter Financial Results Conference Call and Webcast
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced a conference call scheduled for November 9, 2020, at 4:30 p.m. ET to discuss its third-quarter financial results for the period ending September 30, 2020, and provide company updates. Infinity is advancing its first-in-class immuno-oncology product candidate, eganelisib, which selectively inhibits PI3K-gamma and is being evaluated in various clinical studies. Investors can access the call via toll-free and international dial-in numbers or through a live webcast available on Infinity's website.
- Infinity is progressing eganelisib in multiple clinical studies that could enhance its market potential.
- The upcoming conference call allows investors to gain insights into financial results and future direction.
- None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class immuno-oncology product candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), will host a conference call on November 9, 2020 at 4:30 p.m. ET to report its financial results for the third quarter ended September 30, 2020 and provide an update on the company.
Conference Call & Webcast Details |
|
|
Date: |
November 9, 2020 |
|
Time: |
4:30 pm Eastern Time |
|
Toll Free: |
(877) 316-5293 |
|
International: |
(631) 291-4526 |
|
Conference ID: |
1575996 |
|
Webcast: |
A live webcast of the conference call can be accessed in the Investors/Media section of Infinity's website at www.infi.com. An archived version of the webcast will be available on Infinity's website for 30 days.
About Infinity and eganelisib
Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing eganelisib, a first-in-class, oral immuno-oncology development candidate that selectively inhibits PI3K-gamma, in multiple clinical studies. MARIO-275 is a global, randomized, controlled combination study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus AB928 (dual adenosine receptor antagonist) plus Doxil® in advanced TNBC patients. In 2019, Infinity completed enrollment in MARIO-1, a Phase 1/1b study evaluating eganelisib as a monotherapy and in combination with Opdivo (nivolumab) in patients with advanced solid tumors including patients refractory to checkpoint inhibitor therapy. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.
Opdivo® is a registered trademark of Bristol-Myers Squibb.
Tecentriq® and Avastin® are registered trademarks of Roche.
Abraxane® is a registered trademark of Celgene.
Doxil® is a registered trademark of Janssen Products.
